SLP - Simulations Plus, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
33.79
+1.61 (+5.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close32.18
Open32.22
Bid0.00 x 800
Ask0.00 x 2200
Day's Range32.06 - 34.94
52 Week Range17.18 - 34.94
Volume157,203
Avg. Volume72,420
Market Cap592.389M
Beta (3Y Monthly)0.17
PE Ratio (TTM)78.58
EPS (TTM)0.43
Earnings DateN/A
Forward Dividend & Yield0.24 (0.71%)
Ex-Dividend Date2019-07-24
1y Target Est37.00
Trade prices are not sourced from all markets
  • Is Simulations Plus (SLP) Outperforming Other Computer and Technology Stocks This Year?
    Zacks18 hours ago

    Is Simulations Plus (SLP) Outperforming Other Computer and Technology Stocks This Year?

    Is (SLP) Outperforming Other Computer and Technology Stocks This Year?

  • Business Wire3 days ago

    Simulations Plus Enters into New Research Collaboration Agreement with the FDA

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a new five-year Research Collaboration Agreement with the U.S. Food and Drug Administration’s (FDA) Center for Veterinary Medicine to evaluate alternative approaches for determining product bioequivalence (BE) for locally-acting drugs in animals. “It is always exciting to announce ground-breaking collaborations with the FDA and reinforce our partnership as we advance science in new areas,” said Viera Lukacova, director of Simulation Sciences for Simulations Plus and principal investigator on the project.

  • Thomson Reuters StreetEvents8 days ago

    Edited Transcript of SLP earnings conference call or presentation 10-Jul-19 8:15pm GMT

    Q3 2019 Simulations Plus Inc Earnings Call

  • Simulations Plus Inc (SLP) Q3 2019 Earnings Call Transcript
    Motley Fool9 days ago

    Simulations Plus Inc (SLP) Q3 2019 Earnings Call Transcript

    SLP earnings call for the period ending May 31, 2019.

  • Simulations Plus (SLP) Q3 Earnings and Revenues Beat Estimates
    Zacks9 days ago

    Simulations Plus (SLP) Q3 Earnings and Revenues Beat Estimates

    Simulations Plus (SLP) delivered earnings and revenue surprises of 14.29% and 0.88%, respectively, for the quarter ended May 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire9 days ago

    Simulations Plus Reports Third Quarter FY2019 Financial Results

    Record quarter as revenues grow 16%, 9MoFY19 revenues up 13% Board of Directors announces quarterly dividend of $0.06 per share

  • Business Wire10 days ago

    Simulations Plus Upgrades PKPlus™

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced the launch of version 2.5 of PKPlus, an update to its software for analysis of preclinical and clinical trial data. Mark Pflieger, product manager for PKPlus, said: “We delivered several important enhancements, including the simplification of pharmacokinetic (PK) data analyses, as well as automating and streamlining key routines. John DiBella, president of the Lancaster division for Simulations Plus, added: “As the client base for PKPlus has grown, we have engaged with users to identify the core functionality that they need to support the vast majority of their research activities.

  • Simulations Plus (SLP) Reports Next Week: Wall Street Expects Earnings Growth
    Zacks16 days ago

    Simulations Plus (SLP) Reports Next Week: Wall Street Expects Earnings Growth

    Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Simulations Plus (SLP) Earnings Expected to Grow: Should You Buy?
    Zacks17 days ago

    Simulations Plus (SLP) Earnings Expected to Grow: Should You Buy?

    Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire17 days ago

    Simulations Plus Sets Date for 3rd Quarter 2019 Earnings Release and Conference Call

    Conference Call to be on Wednesday, July 10, 2019, at 4:15 PM ET

  • Is Simulations Plus, Inc. (NASDAQ:SLP) A High Quality Stock To Own?
    Simply Wall St.20 days ago

    Is Simulations Plus, Inc. (NASDAQ:SLP) A High Quality Stock To Own?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

  • Business Wire22 days ago

    DILIsym Releases NAFLDsym® Version 2A

    Substantial update of NAFLD drug efficacy software offers a broad range of pathophysiology and over a thousand simulated patients for testing

  • Zacks25 days ago

    Stocks Rise for Third Straight Week

    Stocks Rise for Third Straight Week

  • Business Wirelast month

    Simulations Plus Upgrades Flagship GastroPlus

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has released version 9.7 of its flagship physiologically based pharmacokinetic (PBPK) modeling platform, GastroPlus®.

  • Business Wirelast month

    Cognigen Launches KIWI Version 4.0

    Cognigen Corporation, a Simulations Plus company (SLP) and a leading provider of population pharmacokinetic and pharmacodynamic modeling and simulation services, today announced that it has released Version 4.0 of its KIWI™ Pharmacometric Communication and Collaboration Platform. KIWI is a private cloud-based, validated platform to efficiently and consistently organize, process, visualize, evaluate, and communicate modeling and simulation results. Since the introduction of KIWI 1.0 in 2011, our mission has been to provide pharmacometricians with the most efficient analysis environment possible.

  • New Strong Buy Stocks for June 10th
    Zackslast month

    New Strong Buy Stocks for June 10th

    New Strong Buy Stocks for June 10th

  • Why Fundamental Investors Might Love Simulations Plus, Inc. (NASDAQ:SLP)
    Simply Wall St.2 months ago

    Why Fundamental Investors Might Love Simulations Plus, Inc. (NASDAQ:SLP)

    I've been keeping an eye on Simulations Plus, Inc. (NASDAQ:SLP) because I'm attracted to its fundamentals. Looking at...

  • Business Wire2 months ago

    PMDA Adds Licenses of GastroPlus®

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has received an order from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to add licenses to its GastroPlus® software suite. John DiBella, Lancaster division president for Simulations Plus, said: “The adoption of physiologically based pharmacokinetic (PBPK) modeling to support various applications during the drug development process has increased over the years, partly driven by encouragement from global regulatory agencies.

  • Business Wire2 months ago

    U.S. FDA Renews DILIsym Software Licenses

    DILIsym Services, Inc., a Simulations Plus company (SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that the U.S. Food and Drug Administration has renewed its multi-seat license for the company’s flagship quantitative systems toxicology (QST) modeling software, DILIsym®. The renewal provides DILIsym access to FDA employees across all FDA divisions.

  • Business Wire2 months ago

    Simulations Plus to Present at B. Riley FBR Investor Conference on May 22, 2019

    Simulations Plus, Inc. , a leading provider of software for pharmaceutical discovery and development, today announced that Shawn O’Connor, chief executive officer, will present at the 20th Annual B.

  • Simulations Plus (NASDAQ:SLP) Shareholders Have Enjoyed A Whopping 304% Share Price Gain
    Simply Wall St.2 months ago

    Simulations Plus (NASDAQ:SLP) Shareholders Have Enjoyed A Whopping 304% Share Price Gain

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Business Wire3 months ago

    Lisa LaVange, PhD, Appointed to Board of Directors of Simulations Plus

    Simulations Plus, Inc. (SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced the appointment of Dr. Lisa LaVange to the Company’s Board of Directors. With a distinguished career spanning more than 35 years, Dr. LaVange brings expertise in biostatistics and experience with academia, commercial organizations, including Quintiles, the largest pharmaceutical outsourcing services company in the U.S., and government regulators, including a senior position at the U.S. Food and Drug Administration (FDA).

  • Business Wire3 months ago

    FDA Purchases Bundle of ADMET Predictor® Licenses

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has received an order from the U.S. Food and Drug Administration (FDA) for a 15-user license to its ADMET Predictor® software suite. The purchase was made by the Center for Tobacco Products to support research projects aimed at informing regulatory decision making. John DiBella, Lancaster division president for Simulations Plus, said: “For many years, the FDA has utilized our software across various departments, including the Office of Clinical Pharmacology, Office of Generic Drugs, and Office of Pharmaceutical Quality.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of SLP earnings conference call or presentation 9-Apr-19 8:15pm GMT

    Q2 2019 Simulations Plus Inc Earnings Call

  • Business Wire3 months ago

    Simulations Plus Releases ADMET Predictor® Version 9.5

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has released version 9.5 of its flagship machine learning modeling platform, ADMET Predictor®.